Micromet backs Joseph Lobacki as CCO
This article was originally published in Scrip
Executive Summary
Jospeh Lobacki has joined biopharmaceutical company Micromet, which is developing antibody-based therapies for the treatment of cancer, as senior vice-president and chief commercial officer. Mr Lobacki has 25 years' commercial experience in the biopharmaceutical industry. From 2003 to 2011, he served as senior vice-president and general manager of transplant and oncology at Genzyme.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.